Abstract 2594
Background
Identifying low risk of disease recurrence in localised ccRCC is key for gatekeeping in the adjuvant therapy enrolment. Uncertainty increases the number of patients required for accrual to achieve statistical power. Current scoring systems are good at identifying very low and very high risk cohorts, but have not been proved to be as effective at accurately predicting disease recurrence in intermediate groups. These patients are perhaps those likely to benefit from intervention in addition to surgery, but many may be treated unnecessarily. Using digital pathology, image analysis and machine learning we sought to stratify for risk in this intermediate category.
Methods
Definiens Tissue studio and Developer XD were utilised for object thresholding to measure tumour cell nuclear morphological features on H&E digitised images from 120 ccRCC training set from UK and 217 ccRCC validation set from Singapore. Multiplexed immunofluorescence (mIF) was performed on 120 cases to co-detect neo-vasculature and pan-T cells. An algorithm was derived to measure spatial relationships between blood vessels and T cells. A statistical model was developed by generalised linear model with spatially adaptive local smoothing algorithm, having specificity prefixed (0.8-1) plus cross validation.
Results
Replacing manual nuclear grade with AI aided tumour cell nuclear morphological features improved the specificity of Leibovich score (LS) from 0.76 to 0.86 and from 0.84 to 0.94 in training and validation sets, respectively. Moreover, tumour microenvironment (TM) parameters significantly improved the specificity up to 0.93 in the training set. The negative predictive values of both LS 5 and 6 were zero, but by applying the algorithm the specificity for LS 5 and 6 cases became 0.93 and 0.40 respectively.
Conclusions
By applying image analysis it is possible to identify lower risk for recurrence patients in a conventionally identified intermediate risk group based on routine ccRCC H&E images, and multiplexed TM features. This approach to pathology should help refine selection of patients for clinical trials and form the basis of future AI-enabled prognostic and predictive algorithms in ccRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Authors.
Funding
Renal Cancer Research Fund and NHS Lothian.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract
2888 - Development and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision
Presenter: Kuiyuan Liu
Session: Poster Display session 3
Resources:
Abstract
3607 - Deep learning in nasopharyngeal carcinoma: a retrospective cohort study of 3D convolutional neural networks on magnetic resonance imaging
Presenter: Meng Yun Qiang
Session: Poster Display session 3
Resources:
Abstract
5848 - Combined androgen blockade in patients with advanced androgen receptor–positive salivary gland carcinoma: Exploratory biomarker analyses
Presenter: Chihiro Fushimi
Session: Poster Display session 3
Resources:
Abstract
4484 - Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape
Presenter: Russell Madison
Session: Poster Display session 3
Resources:
Abstract
5753 - Trastuzumab plus docetaxel in patients with advanced HER2–positive salivary duct carcinoma: Exploratory biomarker analyses
Presenter: Hideaki Takahashi
Session: Poster Display session 3
Resources:
Abstract
3373 - Development and characterization of salivary gland cancer organoid cultures
Presenter: Wim Boxtel
Session: Poster Display session 3
Resources:
Abstract
3118 - A parent-of-origin effect of the RB1 mutations in retinoblastoma with low penetrance and variable expressivity
Presenter: Ekaterina Alekseeva
Session: Poster Display session 3
Resources:
Abstract
4512 - The humanistic burden reported by patients diagnosed with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) in Europe
Presenter: Prianka Singh
Session: Poster Display session 3
Resources:
Abstract
3961 - Concurrent Chemotherapy and External Radiation Therapy: An Open Label Non-Inferiority Phase III Randomized Controlled Trial of Weekly versus Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: CONCERT trial
Presenter: ATUL SHARMA
Session: Poster Display session 3
Resources:
Abstract